1
|
Toussaint F, Lepeltier E, Franconi F, Pautu V, Jérôme C, Passirani C, Debuigne A. Diversely substituted poly(N-vinyl amide) derivatives towards non-toxic, stealth and pH-responsive lipid nanocapsules. Colloids Surf B Biointerfaces 2024; 235:113788. [PMID: 38335770 DOI: 10.1016/j.colsurfb.2024.113788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2023] [Revised: 01/22/2024] [Accepted: 02/03/2024] [Indexed: 02/12/2024]
Abstract
Surface modification of lipid nanocapsules (LNC) is necessary to impart stealth properties to these drug carriers and enhance their accumulation into the tumor microenvironment. While pegylation is commonly used to prolong the circulation time of LNC, the increased presence of anti-PEG antibodies in the human population and the internalization issues associated to the PEG shell are strong incentives to search alternatives. This work describes the development of amphiphilic poly(N-vinyl amide)-based (co)polymers, including pH-responsive ones, and their use as LNC modifiers towards improved drug delivery systems. RAFT polymerization gave access to a series of LNC modifiers composed of poly(N-methyl-N-vinyl acetamide), poly(N-vinyl pyrrolidone) or pH-responsive vinylimidazole-based sequence bearing a variety of lipophilic end-groups, namely octadecyl, dioctadecyl or phospholipid groups, for anchoring to the LNC. Decoration of the LNC with these families of poly(N-vinyl amide) derivatives was achieved via both post-insertion and per-formulation methods. This offered valuable and non-toxic LNC protection from opsonization by complement activation, emphasized the benefit of dioctadecyl in the per-formulation approach and highlighted the great potential of poly(N-methyl-N-vinyl acetamide) as PEG alternative. Moreover, incorporation of imidazole moieties in the shell of the carrier imparted pH-responsiveness to the LNC likely to increase the cellular uptake in the acidic tumor microenvironment, opening up new possibilities in the field of active targeting.
Collapse
Affiliation(s)
- François Toussaint
- Center for Education and Research on Macromolecules (CERM), Complex and Entangled Systems from Atoms to Materials Research Unit (CESAM), University of Liège (ULiege), 4000 Liège, Belgium
| | - Elise Lepeltier
- Micro et Nanomédecines Translationnelles (MINT), University of Angers, INSERM 1066, CNRS 6021, Angers, France; Institut Universitaire de France (IUF), France
| | - Florence Franconi
- Micro et Nanomédecines Translationnelles (MINT), University of Angers, INSERM 1066, CNRS 6021, Angers, France
| | - Vincent Pautu
- Micro et Nanomédecines Translationnelles (MINT), University of Angers, INSERM 1066, CNRS 6021, Angers, France
| | - Christine Jérôme
- Center for Education and Research on Macromolecules (CERM), Complex and Entangled Systems from Atoms to Materials Research Unit (CESAM), University of Liège (ULiege), 4000 Liège, Belgium
| | - Catherine Passirani
- Micro et Nanomédecines Translationnelles (MINT), University of Angers, INSERM 1066, CNRS 6021, Angers, France.
| | - Antoine Debuigne
- Center for Education and Research on Macromolecules (CERM), Complex and Entangled Systems from Atoms to Materials Research Unit (CESAM), University of Liège (ULiege), 4000 Liège, Belgium.
| |
Collapse
|
2
|
Idlas P, Lepeltier E, Bastiat G, Pigeon P, McGlinchey MJ, Lautram N, Vessières A, Jaouen G, Passirani C. Physicochemical Characterization of Ferrocifen Lipid Nanocapsules: Customized Drug Delivery Systems Guided by the Molecular Structure. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2023; 39:1885-1896. [PMID: 36693216 DOI: 10.1021/acs.langmuir.2c02910] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
Ferrocifens, lipophilic organometallic complexes, comprise a biologically active redox motif [ferrocenyl-ene-p-phenol] which confers very interesting cytotoxic properties to this family. However, because of their highly lipophilic nature, a formulation stage is required before being administered in vivo. In recent decades, ferrocifen lipid nanocapsules (LNCs) have been successfully formulated and have demonstrated anticancer activity on multidrug-resistant cancers in several mice and rat models (glioblastoma, breast cancer, and metastatic melanoma). A recent family of ferrocifens (succinimidoalkyl-ferrociphenols, including P722) appears to be most efficacious on several resistant cancer cell lines, with IC50 values in the nanomolar range together with promising in vivo results on murine ovarian cancer models. As LNCs are composed of an oily core (caprylic/capric triglycerides), modulation of the succinimido-ferrociphenol lipophilicity could be a valuable approach toward improving the drug loading in LNCs. As the drug loading of the diphenol P722 in LNCs was low, it was structurally modified to increase its lipophilicity and thereby the payload in LNCs. Chemical modification led to a series of five succinimido-ferrocifens. Results confirmed that these slight structural modifications led to increased drug loading in LNCs for all ferrocifens, with no reduction of their cytotoxicity on the SKOV3 ovarian cancer cell line. Interestingly, encapsulation of two of the ferrocifens, diester P769 and monophenolic ester (E)-P998, led to the formation of a gel. This was unprecedented behavior, a phenomenon that could be rationalized in terms of the positioning of ferrocifens in LNCs as shown by the decrease of interfacial tension measurements at the water/oil interface. Moreover, these results highlighted the importance of obtaining a gel of this particular motif, in which the acetylated phenolic ring and the succinimidoalkyl moieties are mutually cis relative to the central double bond. Promising perspectives to use these ferrocifen-loaded LNCs to treat glioblastoma could be readily envisaged by local application of the gel in the cavity after tumor resection.
Collapse
Affiliation(s)
- Pierre Idlas
- Micro et Nanomédecines Translationnelles, MINT, Université Angers, INSERM 1066, CNRS 6021, Angers49100, France
| | - Elise Lepeltier
- Micro et Nanomédecines Translationnelles, MINT, Université Angers, INSERM 1066, CNRS 6021, Angers49100, France
| | - Guillaume Bastiat
- Micro et Nanomédecines Translationnelles, MINT, Université Angers, INSERM 1066, CNRS 6021, Angers49100, France
| | - Pascal Pigeon
- Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire (IPCM), Paris75005, France
- Chimie Paris Tech, PSL University, Paris75005, France
| | | | - Nolwenn Lautram
- Micro et Nanomédecines Translationnelles, MINT, Université Angers, INSERM 1066, CNRS 6021, Angers49100, France
| | - Anne Vessières
- Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire (IPCM), Paris75005, France
| | - Gerard Jaouen
- Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire (IPCM), Paris75005, France
- Chimie Paris Tech, PSL University, Paris75005, France
| | - Catherine Passirani
- Micro et Nanomédecines Translationnelles, MINT, Université Angers, INSERM 1066, CNRS 6021, Angers49100, France
| |
Collapse
|
3
|
Succinimido–Ferrocidiphenol Complexed with Cyclodextrins Inhibits Glioblastoma Tumor Growth In Vitro and In Vivo without Noticeable Adverse Toxicity. Molecules 2022; 27:molecules27144651. [PMID: 35889527 PMCID: PMC9316017 DOI: 10.3390/molecules27144651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 07/12/2022] [Accepted: 07/15/2022] [Indexed: 02/06/2023] Open
Abstract
SuccFerr (N-[4-ferrocenyl,5-5-bis (4-hydroxyphenyl)-pent-4-enyl]-succinimide) has remarkable antiproliferative effects in vitro, attributed to the formation of a stabilized quinone methide. The present article reports in vivo results for a possible preclinical study. SuccFerr is lipophilic and insoluble in water, so the development of a formulation to obviate this inconvenience was necessary. This was achieved by complexation with randomly methylated cyclodextrins (RAMEßCDs). This supramolecular water-soluble system allowed the in vivo experiments below to proceed. Application of SuccFerr on the glioblastoma cancer cell line U87 indicates that it affects the cellular cycle by inducing a blockade at G0/G1 phase, linked to apoptosis, and another one at the S phase, associated with senescence. Using healthy Fischer rats, we show that both intravenous and subcutaneous SuccFerr: RAMEßCD administration at 5 mg/kg lacks toxic effects on several organs. To reach lethality, doses higher than 200 mg/kg need to be administered. These results prompted us to perform an ectopic in vivo study at 1 mg/kg i.v. ferrocidiphenol SuccFerr using F98 cells xenografted in rats. Halting of cancer progression was observed after six days of injection, associated with an immunological defense response linked to the active principle. These results demonstrate that the properties of the selected ferrocidiphenol SuccFerr transfer successfully to in vivo conditions, leading to interesting therapeutic perspectives based on this chemistry.
Collapse
|
4
|
Passirani C, Vessières A, La Regina G, Link W, Silvestri R. Modulating undruggable targets to overcome cancer therapy resistance. Drug Resist Updat 2021; 60:100788. [DOI: 10.1016/j.drup.2021.100788] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 11/17/2021] [Accepted: 11/18/2021] [Indexed: 11/03/2022]
|
5
|
Idlas P, Lepeltier E, Jaouen G, Passirani C. Ferrocifen Loaded Lipid Nanocapsules: A Promising Anticancer Medication against Multidrug Resistant Tumors. Cancers (Basel) 2021; 13:2291. [PMID: 34064748 PMCID: PMC8151583 DOI: 10.3390/cancers13102291] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Revised: 04/29/2021] [Accepted: 05/04/2021] [Indexed: 12/12/2022] Open
Abstract
Resistance of cancer cells to current chemotherapeutic drugs has obliged the scientific community to seek innovative compounds. Ferrocifens, lipophilic organometallic compounds composed of a tamoxifen scaffold covalently bound to a ferrocene moiety, have shown very interesting antiproliferative, cytotoxic and immunologic effects. The formation of ferrocenyl quinone methide plays a crucial role in the multifaceted activity of ferrocifens. Lipid nanocapsules (LNCs), meanwhile, are nanoparticles obtained by a free organic solvent process. LNCs consist of an oily core surrounded by amphiphilic surfactants and are perfectly adapted to encapsulate these hydrophobic compounds. The different in vitro and in vivo experiments performed with this ferrocifen-loaded nanocarrier have revealed promising results in several multidrug-resistant cancer cell lines such as glioblastoma, breast cancer and metastatic melanoma, alone or in combination with other therapies. This review provides an exhaustive summary of the use of ferrocifen-loaded LNCs as a promising nanomedicine, outlining the ferrocifen mechanisms of action on cancer cells, the nanocarrier formulation process and the in vivo results obtained over the last two decades.
Collapse
Affiliation(s)
- Pierre Idlas
- Micro & Nanomedecines Translationnelles (MINT), University of Angers, Inserm, The National Center for Scientific Research (CNRS), SFR ICAT, 49000 Angers, France; (P.I.); (E.L.)
| | - Elise Lepeltier
- Micro & Nanomedecines Translationnelles (MINT), University of Angers, Inserm, The National Center for Scientific Research (CNRS), SFR ICAT, 49000 Angers, France; (P.I.); (E.L.)
| | - Gérard Jaouen
- Sorbonne Universités, Université IPCM, Paris 6, UMR 8232, IPCM, 4 place Jussieu, 75005 Paris, France;
- PSL University, Chimie ParisTech, CNRS, Institut de Recherche de Chimie Paris, 75005 Paris, France
| | - Catherine Passirani
- Micro & Nanomedecines Translationnelles (MINT), University of Angers, Inserm, The National Center for Scientific Research (CNRS), SFR ICAT, 49000 Angers, France; (P.I.); (E.L.)
| |
Collapse
|
6
|
Pautu V, Lepeltier E, Mellinger A, Riou J, Debuigne A, Jérôme C, Clere N, Passirani C. pH-Responsive Lipid Nanocapsules: A Promising Strategy for Improved Resistant Melanoma Cell Internalization. Cancers (Basel) 2021; 13:2028. [PMID: 33922267 PMCID: PMC8122844 DOI: 10.3390/cancers13092028] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Revised: 04/12/2021] [Accepted: 04/16/2021] [Indexed: 12/12/2022] Open
Abstract
Despite significant advances in melanoma therapy, low response rates and multidrug resistance (MDR) have been described, reducing the anticancer efficacy of the administered molecules. Among the causes to explain these resistances, the decreased intratumoral pH is known to potentiate MDR and to reduce the sensitivity to anticancer molecules. Nanomedicines have been widely exploited as the carriers of MDR reversing molecules. Lipid nanocapsules (LNC) are nanoparticles that have already demonstrated their ability to improve cancer treatment. Here, LNC were modified with novel copolymers that combine N-vinylpyrrolidone (NVP) to impart stealth properties and vinyl imidazole (Vim), providing pH-responsive ability to address classical chemoresistance by improving tumor cell entry. These copolymers could be post-inserted at the LNC surface, leading to the property of going from neutral charge under physiological pH to positive charge under acidic conditions. LNC modified with polymer P5 (C18H37-P(NVP21-co-Vim15)) showed in vitro pH-responsive properties characterized by an enhanced cellular uptake under acidic conditions. Moreover, P5 surface modification led to an increased biological effect by protecting the nanocarrier from opsonization by complement activation. These data suggest that pH-sensitive LNC responds to what is expected from a promising nanocarrier to target metastatic melanoma.
Collapse
Affiliation(s)
- Vincent Pautu
- Micro & Nanomedecines Translationnelles (MINT), University of Angers, Inserm, The National Center for Scientific Research (CNRS), SFR ICAT, F-49000 Angers, France; (V.P.); (E.L.); (A.M.); (J.R.); (N.C.)
- Center for Education and Research on Macromolecules (CERM), Complex and Entangled Systems from Atoms to Materials Research Unit (CESAM-RU), University of Liège, 4000 Liège, Belgium; (A.D.); (C.J.)
| | - Elise Lepeltier
- Micro & Nanomedecines Translationnelles (MINT), University of Angers, Inserm, The National Center for Scientific Research (CNRS), SFR ICAT, F-49000 Angers, France; (V.P.); (E.L.); (A.M.); (J.R.); (N.C.)
| | - Adélie Mellinger
- Micro & Nanomedecines Translationnelles (MINT), University of Angers, Inserm, The National Center for Scientific Research (CNRS), SFR ICAT, F-49000 Angers, France; (V.P.); (E.L.); (A.M.); (J.R.); (N.C.)
| | - Jérémie Riou
- Micro & Nanomedecines Translationnelles (MINT), University of Angers, Inserm, The National Center for Scientific Research (CNRS), SFR ICAT, F-49000 Angers, France; (V.P.); (E.L.); (A.M.); (J.R.); (N.C.)
| | - Antoine Debuigne
- Center for Education and Research on Macromolecules (CERM), Complex and Entangled Systems from Atoms to Materials Research Unit (CESAM-RU), University of Liège, 4000 Liège, Belgium; (A.D.); (C.J.)
| | - Christine Jérôme
- Center for Education and Research on Macromolecules (CERM), Complex and Entangled Systems from Atoms to Materials Research Unit (CESAM-RU), University of Liège, 4000 Liège, Belgium; (A.D.); (C.J.)
| | - Nicolas Clere
- Micro & Nanomedecines Translationnelles (MINT), University of Angers, Inserm, The National Center for Scientific Research (CNRS), SFR ICAT, F-49000 Angers, France; (V.P.); (E.L.); (A.M.); (J.R.); (N.C.)
| | - Catherine Passirani
- Micro & Nanomedecines Translationnelles (MINT), University of Angers, Inserm, The National Center for Scientific Research (CNRS), SFR ICAT, F-49000 Angers, France; (V.P.); (E.L.); (A.M.); (J.R.); (N.C.)
| |
Collapse
|
7
|
Vessières A, Wang Y, McGlinchey MJ, Jaouen G. Multifaceted chemical behaviour of metallocene (M = Fe, Os) quinone methides. Their contribution to biology. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2020.213658] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
8
|
Topin-Ruiz S, Mellinger A, Lepeltier E, Bourreau C, Fouillet J, Riou J, Jaouen G, Martin L, Passirani C, Clere N. p722 ferrocifen loaded lipid nanocapsules improve survival of murine xenografted-melanoma via a potentiation of apoptosis and an activation of CD8 + T lymphocytes. Int J Pharm 2020; 593:120111. [PMID: 33246045 DOI: 10.1016/j.ijpharm.2020.120111] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Revised: 11/12/2020] [Accepted: 11/19/2020] [Indexed: 01/13/2023]
Abstract
Metastatic melanoma is a malignant tumor with a poor prognosis. Recent new therapeutics improved the survival of patients at a metastatic stage. However, the low response rate to immunotherapy, explained in part by resistance to apoptosis, needs to develop new strategies. The ferrocifen family represents promising bioorganometallic molecules for melanoma treatment since they show potent anticancer properties. The aim of this study is (i) to evaluate the benefits of a strategy involving encapsulated p722 in lipid nanocapsules (LNC) in B16F10 melanoma mice models and (ii) to compare the beneficial effects with an existing therapy such as anti-CTLA4 mAb. Interestingly, LNC-p722 induces a significant decrease of melanoma cell viability. In vivo data shows a significant improvement in the survival rate and a slower tumor growth with p722-loaded LNC in comparison with anti-CTLA4 mAb. Western blots confirm that LNC-p722 potentiates intrinsic apoptotic pathway. Treatment with LNC-p722 significantly activates CD8+ T lymphocytes compared to treatment with anti-CTLA4 mAb. This study uncovers a new therapeutic strategy with encapsulated p722 to prevent B16F10 melanoma growth and to improve survival of treated mice.
Collapse
Affiliation(s)
- Solène Topin-Ruiz
- MINT, Univ Angers, INSERM, CNRS, IBS-CHU, 4 rue Larrey, F-49933 Angers, France; Centre Hospitalier Universitaire, service de dermatologie, 4 rue Larrey, F-49933 Angers, France
| | - Adélie Mellinger
- MINT, Univ Angers, INSERM, CNRS, IBS-CHU, 4 rue Larrey, F-49933 Angers, France
| | - Elise Lepeltier
- MINT, Univ Angers, INSERM, CNRS, IBS-CHU, 4 rue Larrey, F-49933 Angers, France
| | - Clara Bourreau
- MINT, Univ Angers, INSERM, CNRS, IBS-CHU, 4 rue Larrey, F-49933 Angers, France
| | - Juliette Fouillet
- MINT, Univ Angers, INSERM, CNRS, IBS-CHU, 4 rue Larrey, F-49933 Angers, France
| | - Jérémie Riou
- MINT, Univ Angers, INSERM, CNRS, IBS-CHU, 4 rue Larrey, F-49933 Angers, France
| | - Gérard Jaouen
- PSL, Chimie ParisTech, Paris Cedex 05, France; Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire (IPCM, UMR 8232), Paris Cedex 05, France
| | - Ludovic Martin
- Centre Hospitalier Universitaire, service de dermatologie, 4 rue Larrey, F-49933 Angers, France
| | - Catherine Passirani
- MINT, Univ Angers, INSERM, CNRS, IBS-CHU, 4 rue Larrey, F-49933 Angers, France
| | - Nicolas Clere
- MINT, Univ Angers, INSERM, CNRS, IBS-CHU, 4 rue Larrey, F-49933 Angers, France.
| |
Collapse
|
9
|
Bouché M, Hognon C, Grandemange S, Monari A, Gros PC. Recent advances in iron-complexes as drug candidates for cancer therapy: reactivity, mechanism of action and metabolites. Dalton Trans 2020; 49:11451-11466. [PMID: 32776052 DOI: 10.1039/d0dt02135k] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
In this perspective, we discuss iron-complexes as drug candidates that are promising alternatives to conventional platinum-based chemotherapies owing to their broad range of reactivities and to the targeting of different biological systems. Breakthroughs in the comprehension of iron complexes' structure-activity relationship contributed to the clarification of their metabolization pathways, sub-cellular localization and influence on iron homeostasis, while enlightening the primary molecular targets of theses likely multi-target metallodrugs. Both the antiproliferative activity and elevated safety index observed among the family of iron complexes showed encouraging results as per their therapeutic potential and selectivity also with the aim of reducing chemotherapy side-effects, and facilitated more pre-clinical investigations. The purpose of this perspective is to summarize the recent advances that contributed in unveiling the intricate relationships between the structural modifications on iron-complexes and their reactivity, cellular trafficking and global mechanisms of action to broaden their use as anticancer drugs and advance to clinical evaluation.
Collapse
Affiliation(s)
- Mathilde Bouché
- Université de Lorraine, CNRS, L2CM UMR 7053, F-54000 Nancy, France.
| | - Cécilia Hognon
- Université de Lorraine, CNRS, LPCT UMR 7019, F-54000 Nancy, France
| | | | - Antonio Monari
- Université de Lorraine, CNRS, LPCT UMR 7019, F-54000 Nancy, France
| | - Philippe C Gros
- Université de Lorraine, CNRS, L2CM UMR 7053, F-54000 Nancy, France.
| |
Collapse
|
10
|
Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches. ADVANCED THERAPEUTICS 2020. [DOI: 10.1002/adtp.202000124] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
11
|
Bhargav AG, Mondal SK, Garcia CA, Green JJ, Quiñones‐Hinojosa A. Nanomedicine Revisited: Next Generation Therapies for Brain Cancer. ADVANCED THERAPEUTICS 2020. [DOI: 10.1002/adtp.202000118] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Adip G. Bhargav
- Mayo Clinic College of Medicine and Science Mayo Clinic 200 First Street SW Rochester MN 55905 USA
- Department of Neurologic Surgery Mayo Clinic 4500 San Pablo Rd. Jacksonville FL 32224 USA
| | - Sujan K. Mondal
- Department of Pathology University of Pittsburgh School of Medicine 200 Lothrop Street Pittsburgh PA 15213 USA
| | - Cesar A. Garcia
- Department of Neurologic Surgery Mayo Clinic 4500 San Pablo Rd. Jacksonville FL 32224 USA
| | - Jordan J. Green
- Departments of Biomedical Engineering, Neurosurgery, Oncology, Ophthalmology, Materials Science and Engineering, and Chemical and Biomolecular Engineering, Translational Tissue Engineering Center, Bloomberg‐Kimmel Institute for Cancer Immunotherapy, Institute for Nanobiotechnology Johns Hopkins University School of Medicine 400 N. Broadway, Smith 5017 Baltimore MD 21231 USA
| | - Alfredo Quiñones‐Hinojosa
- Department of Neurologic Surgery Mayo Clinic 4500 San Pablo Rd. Jacksonville FL 32224 USA
- Departments of Otolaryngology‐Head and Neck Surgery/Audiology Neuroscience, Cancer Biology, and Anatomy Mayo Clinic 4500 San Pablo Rd. Jacksonville FL 32224 USA
| |
Collapse
|
12
|
Vinayak M, Maurya AK. Quercetin Loaded Nanoparticles in Targeting Cancer: Recent Development. Anticancer Agents Med Chem 2020; 19:1560-1576. [PMID: 31284873 DOI: 10.2174/1871520619666190705150214] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 05/23/2019] [Accepted: 05/23/2019] [Indexed: 12/27/2022]
Abstract
The spread of metastatic cancer cell is the main cause of death worldwide. Cellular and molecular basis of the action of phytochemicals in the modulation of metastatic cancer highlights the importance of fruits and vegetables. Quercetin is a natural bioflavonoid present in fruits, vegetables, seeds, berries, and tea. The cancer-preventive activity of quercetin is well documented due to its anti-inflammatory, anti-proliferative and anti-angiogenic activities. However, poor water solubility and delivery, chemical instability, short half-life, and low-bioavailability of quercetin limit its clinical application in cancer chemoprevention. A better understanding of the molecular mechanism of controlled and regulated drug delivery is essential for the development of novel and effective therapies. To overcome the limitations of accessibility by quercetin, it can be delivered as nanoconjugated quercetin. Nanoconjugated quercetin has attracted much attention due to its controlled drug release, long retention in tumor, enhanced anticancer potential, and promising clinical application. The pharmacological effect of quercetin conjugated nanoparticles typically depends on drug carriers used such as liposomes, silver nanoparticles, silica nanoparticles, PLGA (Poly lactic-co-glycolic acid), PLA (poly(D,L-lactic acid)) nanoparticles, polymeric micelles, chitosan nanoparticles, etc. In this review, we described various delivery systems of nanoconjugated quercetin like liposomes, silver nanoparticles, PLGA (Poly lactic-co-glycolic acid), and polymeric micelles including DOX conjugated micelles, metal conjugated micelles, nucleic acid conjugated micelles, and antibody-conjugated micelles on in vitro and in vivo tumor models; as well as validated their potential as promising onco-therapeutic agents in light of recent updates.
Collapse
Affiliation(s)
- Manjula Vinayak
- Biochemistry & Molecular Biology Laboratory, Centre for Advanced Study in Zoology, Institute of Science, Banaras Hindu University, Varanasi-221005, India
| | - Akhilendra K Maurya
- Biochemistry & Molecular Biology Laboratory, Centre for Advanced Study in Zoology, Institute of Science, Banaras Hindu University, Varanasi-221005, India.,Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States
| |
Collapse
|
13
|
Clavreul A, Roger E, Pourbaghi-Masouleh M, Lemaire L, Tétaud C, Menei P. Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma. Drug Deliv 2019; 25:1756-1765. [PMID: 30338715 PMCID: PMC6225440 DOI: 10.1080/10717544.2018.1507061] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Anticancer agents that target both tumor cells and angiogenesis are of potential interest for glioblastoma (GB) therapy. One such agent is sorafenib (SFN), a tyrosine kinase inhibitor. However, poor aqueous solubility and undesirable side effects limit its clinical application, including local treatment. We encapsulated SFN in lipid nanocapsules (LNCs) to overcome these drawbacks. LNCs are nanocarriers formulated according to a solvent-free process, using only components that have received regulatory approval. SFN-LNCs had a diameter of 54 ± 1 nm, high encapsulation efficiency (>90%), and a drug payload of 2.11 ± 0.03 mg/g of LNC dispersion. They inhibited in vitro angiogenesis and decreased human U87MG GB cell viability similarly to free SFN. In vivo studies showed that the intratumoral administration of SFN-LNCs or free SFN in nude mice bearing an orthotopic U87MG human GB xenograft decreased the proportion of proliferating cells in the tumor relative to control groups. SFN-LNCs were more effective than free SFN for inducing early tumor vascular normalization, characterized by increases in tumor blood flow and decreases in tumor vessel area. These results highlight the potential of LNCs as delivery systems for SFN. The vascular normalization induced by SFN-LNCs could be used to improve the efficacy of chemotherapy or radiotherapy for treating GB.
Collapse
Affiliation(s)
- Anne Clavreul
- a Département de Neurochirurgie , CHU , Angers , France.,b CRCINA, INSERM , Université de Nantes, Université d'Angers , Angers , France
| | - Emilie Roger
- c MINT, INSERM 1066, CNRS 6021 , Université d'Angers, UNIV Angers , Angers , France
| | - Milad Pourbaghi-Masouleh
- b CRCINA, INSERM , Université de Nantes, Université d'Angers , Angers , France.,d Division of Drug Delivery and Tissue Engineering, School of Pharmacy , University of Nottingham , Nottingham , UK
| | - Laurent Lemaire
- c MINT, INSERM 1066, CNRS 6021 , Université d'Angers, UNIV Angers , Angers , France.,e PRISM-IRM , UNIV Angers , Angers , France
| | - Clément Tétaud
- b CRCINA, INSERM , Université de Nantes, Université d'Angers , Angers , France
| | - Philippe Menei
- a Département de Neurochirurgie , CHU , Angers , France.,b CRCINA, INSERM , Université de Nantes, Université d'Angers , Angers , France
| |
Collapse
|
14
|
Abstract
Many ferrocene complexes have been prepared for their oncological potential. Some derive from molecules with known biological effects (taxanes, podophyllotoxine, artemisine, SAHA, etc.) while others are synthetic molecules selected for their cytotoxic effects (N-alkylaminoferrocenes and ferrocenyl alkylpyridinium). Although these complexes have received a great deal of attention, the field of iron metallodrugs is not limited to them. A number of inorganic complexes of iron(ii) and iron(iii) with possible anticancer effects have also been published, although research into their biological effects is often only at an early stage. This chapter also includes iron chelators, molecules that are administered in non-metallic form but whose cytotoxic species are their coordination complexes of iron generated in vivo. The most emblematic molecule of this family is bleomycin, used as an anticancer agent in many chemotherapies. To these can be added the iron chelates originally synthesized to treat iron overload, some of which have been shown to possess interesting anticancer properties. They have been, and continue to be, the subject of many clinical trials, whether alone or in combination. Thus, the area of iron metallodrugs includes molecules with very different structures and reactivity, studied from a number of different perspectives, but focused on increasing the number of molecules at our disposal for combatting cancer.
Collapse
Affiliation(s)
- Anne Vessieres
- Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire, UMR CNRS 8232 4, Place Jussieu F-75005 Paris France
| |
Collapse
|
15
|
Briot T, Roger E, Bou Haidar N, Bejaud J, Lautram N, Guillet C, Thépot S, Legeay S, Lagarce F. Di- O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity. Int J Nanomedicine 2019; 14:2091-2102. [PMID: 30988610 PMCID: PMC6440450 DOI: 10.2147/ijn.s190482] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Background Acute myeloid leukemia mainly affects adult patients. Complete remission for patients younger than 60 years, who are candidates for standard induction therapy, is achieved in 60%–80% of cases. However, the prognosis is still poor for older patients, who are unfit for intensive chemotherapy, and only a few therapies are available. Hypomethylating agents, such as decitabine, are approved for such patients. The current dosing regimen consists of one administration per day, for 5 days, each 4 weeks. Methods Here, we present the synthesis of a decitabine prodrug, combined with its encapsulation into a lipid-based nanocapsule formulation. Decitabine (C12)2 was synthetized, then loaded into nanocapsules. Its stability in phosphate buffer ans human plasma was checked. Its activity was evaluated by Cell proliferation assays and cell-cycle analysis on human erythroleukemia cells. Then its pharmacokinetics was determined on a rat model. Results Decitabine (C12)2 was obtained with a yield of 50%. Drug loading into nanocarriers of 27.45±0.05 nm was 5.8±0.5 mg/mL. The stability of decitabine was improved and its activity on leukemia cells was not altered. Finally, pharmacokinetics studies showed a prolonged mean residence time of the drug. Conclusion Decitabine (C12)2 as a prodrug showed high encapsulation efficiency, a good stability in plasma with no impact on its activity on leukemia cells and improved pharmacokinetics.
Collapse
Affiliation(s)
- Thomas Briot
- Micro & Nanomédecines Translationelles - MINT, UNIV Angers, INSERM 1066, CNRS 6021, University of Angers, MINT IBS-CHU, Larrey, 49933 Angers, France, .,University Hospital of Angers, Pharmacy Department, 49933 Angers, France,
| | - Emilie Roger
- Micro & Nanomédecines Translationelles - MINT, UNIV Angers, INSERM 1066, CNRS 6021, University of Angers, MINT IBS-CHU, Larrey, 49933 Angers, France,
| | - Naila Bou Haidar
- Micro & Nanomédecines Translationelles - MINT, UNIV Angers, INSERM 1066, CNRS 6021, University of Angers, MINT IBS-CHU, Larrey, 49933 Angers, France,
| | - Jerome Bejaud
- Micro & Nanomédecines Translationelles - MINT, UNIV Angers, INSERM 1066, CNRS 6021, University of Angers, MINT IBS-CHU, Larrey, 49933 Angers, France,
| | - Nolwenn Lautram
- Micro & Nanomédecines Translationelles - MINT, UNIV Angers, INSERM 1066, CNRS 6021, University of Angers, MINT IBS-CHU, Larrey, 49933 Angers, France,
| | - Catherine Guillet
- University of Angers, Molecular and Cellular Analysis Platform, IBS-CHU, 49933 Angers, France
| | - Sylvain Thépot
- University Hospital of Angers, Hematology, 49933 Angers, France.,INSERM CRCINA, University of Angers, 49933 Angers, France
| | - Samuel Legeay
- Micro & Nanomédecines Translationelles - MINT, UNIV Angers, INSERM 1066, CNRS 6021, University of Angers, MINT IBS-CHU, Larrey, 49933 Angers, France,
| | - Frederic Lagarce
- Micro & Nanomédecines Translationelles - MINT, UNIV Angers, INSERM 1066, CNRS 6021, University of Angers, MINT IBS-CHU, Larrey, 49933 Angers, France, .,University Hospital of Angers, Pharmacy Department, 49933 Angers, France,
| |
Collapse
|
16
|
Zaki M, Hairat S, Aazam ES. Scope of organometallic compounds based on transition metal-arene systems as anticancer agents: starting from the classical paradigm to targeting multiple strategies. RSC Adv 2019; 9:3239-3278. [PMID: 35518979 PMCID: PMC9060267 DOI: 10.1039/c8ra07926a] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Accepted: 12/26/2018] [Indexed: 02/02/2023] Open
Abstract
The advent of the clinically approved drug cisplatin started a new era in the design of metallodrugs for cancer chemotherapy. However, to date, there has not been much success in this field due to the persistence of some side effects and multi-drug resistance of cancer cells. In recent years, there has been increasing interest in the design of metal chemotherapeutics using organometallic complexes due to their good stability and unique properties in comparison to normal coordination complexes. Their intermediate properties between that of traditional inorganic and organic materials provide researchers with a new platform for the development of more promising cancer therapeutics. Classical metal-based drugs exert their therapeutic potential by targeting only DNA, but in the case of organometallic complexes, their molecular target is quite distinct to avoid drug resistance by cancer cells. Some organometallic drugs act by targeting a protein or inhibition of enzymes such as thioredoxin reductase (TrRx), while some target mitochondria and endoplasmic reticulum. In this review, we mainly discuss organometallic complexes of Ru, Ti, Au, Fe and Os and their mechanisms of action and how new approaches improve their therapeutic potential towards various cancer phenotypes. Herein, we discuss the role of structure-reactivity relationships in enhancing the anticancer potential of drugs for the benefit of humans both in vitro and in vivo. Besides, we also include in vivo tumor models that mimic human physiology to accelerate the development of more efficient clinical organometallic chemotherapeutics.
Collapse
Affiliation(s)
- Mehvash Zaki
- Department of Chemistry, King Abdulaziz University Jeddah Saudia Arabia +91 8979086156, +966 561835672
| | - Suboot Hairat
- Department of Biotechnology, Wachemo University Hossana Ethiopia
| | - Elham S Aazam
- Department of Chemistry, King Abdulaziz University Jeddah Saudia Arabia +91 8979086156, +966 561835672
| |
Collapse
|
17
|
Karim R, Lepeltier E, Esnault L, Pigeon P, Lemaire L, Lépinoux-Chambaud C, Clere N, Jaouen G, Eyer J, Piel G, Passirani C. Enhanced and preferential internalization of lipid nanocapsules into human glioblastoma cells: effect of a surface-functionalizing NFL peptide. NANOSCALE 2018; 10:13485-13501. [PMID: 29972178 DOI: 10.1039/c8nr02132e] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Increasing intracellular drug concentration using nanocarriers can be a potential strategy to improve efficacy against glioblastoma (GBM). Here, the fluorescent-labelled NFL-TBS·40-63 peptide (fluoNFL) concentration on a lipid nanocapsule (LNC) was studied to enhance nanovector internalization into human GBM cells. LNC surface-functionalization with various fluoNFL concentrations was performed by adsorption. LNC size and surface charge altered gradually with increasing peptide concentration, but their complement protein consumption remained low. Desorption of fluoNFL from the LNC surface was found to be slow. Furthermore, it was observed that the rate and extent of LNC internalization in the U87MG human glioblastoma cells were dependent on the surface-functionalizing fluoNFL concentration. In addition, we showed that the uptake of fluoNFL-functionalized LNCs was preferential towards U87MG cells compared to healthy human astrocytes. The fluoNFL-functionalized LNC internalization into the U87MG cells was energy-dependent and occurred possibly by macropinocytosis and clathrin-mediated and caveolin-mediated endocytosis. A new ferrocifen-type molecule (FcTriOH), as a potent anticancer candidate, was then encapsulated in the LNCs and the functionalization improved its in vitro efficacy compared to other tested formulations against U87MG cells. In the preliminary study, on subcutaneous human GBM tumor model in nude mice, a significant reduction of relative tumor volume was observed at one week after the second intravenous injection with FcTriOH-loaded LNCs. These results showed that enhancing NFL peptide concentration on the LNC surface is a promising approach for increased and preferential nanocarrier internalization into human GBM cells, and the FcTriOH-loaded LNCs are a promising therapy approach for GBM.
Collapse
Affiliation(s)
- Reatul Karim
- MINT, UNIV Angers, INSERM 1066, CNRS 6021, Angers, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Daum S, Babiy S, Konovalova H, Hofer W, Shtemenko A, Shtemenko N, Janko C, Alexiou C, Mokhir A. Tuning the structure of aminoferrocene-based anticancer prodrugs to prevent their aggregation in aqueous solution. J Inorg Biochem 2018; 178:9-17. [DOI: 10.1016/j.jinorgbio.2017.08.038] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Revised: 08/24/2017] [Accepted: 08/30/2017] [Indexed: 11/27/2022]
|
19
|
Briot T, Roger E, Lautram N, Verger A, Clavreul A, Lagarce F. Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia. Int J Nanomedicine 2017; 12:8427-8442. [PMID: 29200853 PMCID: PMC5703174 DOI: 10.2147/ijn.s147659] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Decitabine is a hydrophilic drug that acts by hypomethylating DNA. Decitabine is used in Europe for the treatment of acute myeloid leukemia (AML) in patients aged ≥65 years. However, it can only be administered intravenously due to very low oral bioavailability and a large distribution volume. Oral administration would allow outpatient treatment, improving quality of life and reducing treatment costs. The present study proposes to develop lipid nanocapsules (LNCs), originally designed for lipophilic drugs, to encapsulate decitabine. Two different formulations of LNCs were designed: LNCs based on a high proportion of Transcutol® HP (THP-LNCs) and LNCs associated with a mixture of Transcutol® HP and Tween® 80 (THP-T80-LNCs). The second formulation had a diameter of 26.5±0.5 nm, high encapsulation efficiency (>85%), and a drug payload of 472±64 µg/mL. Decitabine-loaded THP-T80-LNC cytotoxicity was evaluated on two AML cell lines depending on their decitabine resistance: HEL (not resistant) and HL-60 (resistant). The permeability of decitabine-loaded THP-T80-LNCs was also evaluated on Caco-2 cell monolayers. Decitabine cytotoxicity against HEL and HL-60 was higher when decitabine was loaded in THP-T80-LNCs than when free. Apparent permeability on Caco-2 cell monolayers was also increased, suggesting a potentially useful formulation to increase the oral bioavailability of decitabine.
Collapse
Affiliation(s)
- Thomas Briot
- Micro & Nanomédecines Translationelles - MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, MINT IBS-CHU.,Pharmacy Department, University Hospital of Angers
| | - Emilie Roger
- Micro & Nanomédecines Translationelles - MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, MINT IBS-CHU
| | - Nolwenn Lautram
- Micro & Nanomédecines Translationelles - MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, MINT IBS-CHU
| | - Alexis Verger
- Micro & Nanomédecines Translationelles - MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, MINT IBS-CHU
| | - Anne Clavreul
- Neurosurgery Department, University Hospital of Angers.,CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France
| | - Frederic Lagarce
- Micro & Nanomédecines Translationelles - MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, MINT IBS-CHU.,Pharmacy Department, University Hospital of Angers
| |
Collapse
|
20
|
Wang Y, Dansette PM, Pigeon P, Top S, McGlinchey MJ, Mansuy D, Jaouen G. A new generation of ferrociphenols leads to a great diversity of reactive metabolites, and exhibits remarkable antiproliferative properties. Chem Sci 2017; 9:70-78. [PMID: 29629075 PMCID: PMC5870192 DOI: 10.1039/c7sc04213b] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Accepted: 11/09/2017] [Indexed: 12/22/2022] Open
Abstract
Two chemotypes of quinone methide pathways from a single substrate are reported, which may be linked to its remarkable antiproliferative activity.
Organometallic compounds bearing the redox motif [ferrocenyl-ene-phenol] have very promising antiproliferative properties which have been further improved by incorporating pertinent substituents able to engender new mechanisms. Here we show that novel ferrociphenols bearing a hydroxypropyl chain exhibit strong antiproliferative effects, in most cases much better than those of cisplatin, tamoxifen, or of previously described ferrociphenols devoid of this terminal OH. This is illustrated, in the case of one of these compounds, by its IC50 values of 110 nM for MDA-MB-231 triple negative breast cancer cells and of 300 nM for cisplatin-resistant A2780cisR human ovarian cancer cells, and by its GI50 values lower than 100 nM towards a series of melanoma and renal cancer cell lines of the NCI-60 panel. Interestingly, oxidative metabolism of these hydroxypropyl-ferrociphenols yields two kinds of quinone methides (QMs) that readily react with various nucleophiles, such as glutathione, to give 1,6- and 1,8-adducts. Protonation of these quinone methides generates numerous reactive metabolites leading eventually to many rearrangement and cleavage products. This unprecedented and fully characterized metabolic profile involving a wide range of electrophilic metabolites that should react with cell macromolecules may be linked to the remarkable profile of antiproliferative activities of this new series. Indeed, the great diversity of unexpected reactive metabolites found upon oxidation will allow them to adapt to various situations present in the cancer cell. These data initiate a novel strategy for the rational design of anticancer molecules, thus opening the way to new organometallic potent anticancer drug candidates for the treatment of chemoresistant cancers.
Collapse
Affiliation(s)
- Yong Wang
- PSL , Chimie ParisTech , 11 rue Pierre et Marie Curie , F-75005 Paris , France.,Sorbonne Universités , UPMC Univ Paris 6 , UMR 8232 CNRS , IPCM , Place Jussieu , F-75005 Paris , France . ;
| | - Patrick M Dansette
- Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques , UMR 8601 CNRS , Université Paris Descartes , PRES Paris Cité Sorbonne , 45 rue des Saints Pères , 75270 Paris Cedex 06 , France .
| | - Pascal Pigeon
- PSL , Chimie ParisTech , 11 rue Pierre et Marie Curie , F-75005 Paris , France.,Sorbonne Universités , UPMC Univ Paris 6 , UMR 8232 CNRS , IPCM , Place Jussieu , F-75005 Paris , France . ;
| | - Siden Top
- Sorbonne Universités , UPMC Univ Paris 6 , UMR 8232 CNRS , IPCM , Place Jussieu , F-75005 Paris , France . ;
| | - Michael J McGlinchey
- UCD School of Chemistry and Chemical Biology , University College Dublin , Belfield , Dublin 4 , Ireland
| | - Daniel Mansuy
- Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques , UMR 8601 CNRS , Université Paris Descartes , PRES Paris Cité Sorbonne , 45 rue des Saints Pères , 75270 Paris Cedex 06 , France .
| | - Gérard Jaouen
- PSL , Chimie ParisTech , 11 rue Pierre et Marie Curie , F-75005 Paris , France.,Sorbonne Universités , UPMC Univ Paris 6 , UMR 8232 CNRS , IPCM , Place Jussieu , F-75005 Paris , France . ;
| |
Collapse
|
21
|
Abstract
Glioblastoma is the most aggressive brain tumor and, even with the current multimodal therapy, is an invariably lethal cancer with a life expectancy that depends on the tumor subtype but, even in the most favorable cases, rarely exceeds 2 years. Epigenetic factors play an important role in gliomagenesis, are strong predictors of outcome, and are important determinants for the resistance to radio- and chemotherapy. The latest addition to the epigenetic machinery is the noncoding RNA (ncRNA), that is, RNA molecules that are not translated into a protein and that exert their function by base pairing with other nucleic acids in a reversible and nonmutational mode. MicroRNAs (miRNA) are a class of ncRNA of about 22 bp that regulate gene expression by binding to complementary sequences in the mRNA and silence its translation into proteins. MicroRNAs reversibly regulate transcription through nonmutational mechanisms; accordingly, they can be considered as epigenetic effectors. In this review, we will discuss the role of miRNA in glioma focusing on their role in drug resistance and on their potential applications in the therapy of this tumor.
Collapse
|
22
|
Karim R, Palazzo C, Laloy J, Delvigne AS, Vanslambrouck S, Jerome C, Lepeltier E, Orange F, Dogne JM, Evrard B, Passirani C, Piel G. Development and evaluation of injectable nanosized drug delivery systems for apigenin. Int J Pharm 2017; 532:757-768. [PMID: 28456651 DOI: 10.1016/j.ijpharm.2017.04.064] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2017] [Revised: 04/21/2017] [Accepted: 04/25/2017] [Indexed: 12/16/2022]
Abstract
The purpose of this study was to develop different injectable nanosized drug delivery systems (NDDSs) i.e. liposome, lipid nanocapsule (LNC) and polymeric nanocapsule (PNC) encapsulating apigenin (AG) and compare their characteristics to identify the nanovector(s) that can deliver the largest quantity of AG while being biocompatible. Two liposomes with different surface characteristics (cationic and anionic), a LNC and a PNC were prepared. A novel tocopherol modified poly(ethylene glycol)-b-polyphosphate block-copolymer was used for the first time for the PNC preparation. The NDDSs were compared by their physicochemical characteristics, AG release, storage stability, stability in serum, complement consumption and toxicity against a human macrovascular endothelial cell line (EAhy926). The diameter and surface charge of the NDDSs were comparable with previously reported injectable nanocarriers. The NDDSs showed good encapsulation efficiency and drug loading. Moreover, the NDDSs were stable during storage and in fetal bovine serum for extended periods, showed low complement consumption and were non-toxic to EAhy926 cells up to high concentrations. Therefore, they can be considered as potential injectable nanocarriers of AG. Due to less pronounced burst effect and extended release characteristics, the nanocapsules could be favorable approaches for achieving prolonged pharmacological activity of AG using injectable NDDS.
Collapse
Affiliation(s)
- Reatul Karim
- Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liege, Liege, Belgium; MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, Angers, France.
| | - Claudio Palazzo
- Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liege, Liege, Belgium
| | - Julie Laloy
- Namur Nanosafety Centre, NARILIS, Department of Pharmacy, University of Namur, Namur, Belgium
| | - Anne-Sophie Delvigne
- Namur Nanosafety Centre, NARILIS, Department of Pharmacy, University of Namur, Namur, Belgium
| | - Stéphanie Vanslambrouck
- Center for Education and Research on Macromolecules (CERM), University of Liege, UR-CESAM, Liege, Belgium
| | - Christine Jerome
- Center for Education and Research on Macromolecules (CERM), University of Liege, UR-CESAM, Liege, Belgium
| | - Elise Lepeltier
- MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, Angers, France
| | - Francois Orange
- Université Côte d'Azur, Centre Commun de Microscopie Appliquée, Nice, France
| | - Jean-Michel Dogne
- Namur Nanosafety Centre, NARILIS, Department of Pharmacy, University of Namur, Namur, Belgium
| | - Brigitte Evrard
- Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liege, Liege, Belgium
| | - Catherine Passirani
- MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, Angers, France
| | - Géraldine Piel
- Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liege, Liege, Belgium
| |
Collapse
|
23
|
Safwat S, Ishak RA, Hathout RM, Mortada ND. Statins anticancer targeted delivery systems: re-purposing an old molecule. ACTA ACUST UNITED AC 2017; 69:613-624. [PMID: 28271498 DOI: 10.1111/jphp.12707] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Accepted: 01/12/2017] [Indexed: 01/01/2023]
Abstract
OBJECTIVES Exploring the use of statins as anticancer agents and exploiting different drug delivery systems in targeting these molecules to cancerous sites. Literature review was performed to investigate the use of statins in cancer treatment in one hand, and the different pharmaceutical approaches to deliver and target these drugs to their site of action. KEY FINDINGS Statins were used for decades as antihypercholestrolemic drugs but recently have been proven potential for broad anticancer activities. The incorporation of statins in nanoparticulate drug delivery systems not only augmented the cytotoxicity of statins but also overcame the resistance of cancerous cells against the traditional chemotherapeutic agents. Statins-loaded nanoparticles could be easily tampered to target the cancerous cells and consequently minimal drug amount could be utilized. SUMMARY This review reconnoitered the different endeavors to incorporate statins in various nanoparticles and summarized the successful effects in targeting cancerous cells and reducing their proliferation without the side effects of commonly used chemotherapeutic agents.
Collapse
Affiliation(s)
- Sally Safwat
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt
| | - Rania A Ishak
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt
| | - Rania M Hathout
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt
| | - Nahed D Mortada
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt
| |
Collapse
|
24
|
Dermal quercetin lipid nanocapsules: Influence of the formulation on antioxidant activity and cellular protection against hydrogen peroxide. Int J Pharm 2017; 518:167-176. [DOI: 10.1016/j.ijpharm.2016.12.043] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Revised: 12/10/2016] [Accepted: 12/17/2016] [Indexed: 01/13/2023]
|
25
|
Resnier P, Galopin N, Sibiril Y, Clavreul A, Cayon J, Briganti A, Legras P, Vessières A, Montier T, Jaouen G, Benoit JP, Passirani C. Efficient ferrocifen anticancer drug and Bcl-2 gene therapy using lipid nanocapsules on human melanoma xenograft in mouse. Pharmacol Res 2017; 126:54-65. [PMID: 28159700 DOI: 10.1016/j.phrs.2017.01.031] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2017] [Revised: 01/26/2017] [Accepted: 01/27/2017] [Indexed: 12/22/2022]
Abstract
Metastatic melanoma has been described as a highly aggressive cancer with low sensibility to chemotherapeutic agents. New types of drug, such as metal-based drugs (ferrocifens) have emerged and could represent an alternative for melanoma treatment since they show interesting anticancer potential. Furthermore, molecular analysis has evidenced the role of apoptosis in the low sensibility of melanomas and especially of the key regulator, Bcl-2. The objective of this study was to combine two strategies in the same lipid nanocapsules (LNCs): i) gene therapy to modulate anti-apoptotic proteins by the use of Bcl-2 siRNA, and ii) ferrocifens as a new type of anticancer agent. The efficient gene silencing with LNCs was verified by the specific extinction of Bcl-2 in melanoma cells. The cellular toxicity of ferrocifens (ferrociphenol (FcDiOH) or Ansa-FcDiOH) was demonstrated, showing higher efficacy than dacarbazine. Interestingly, the association of siBcl-2 LNCs with Ansa-FcDiOH demonstrated a significant effect on melanoma cell viability. Moreover, the co-encapsulation of siRNA and ferrocifens was successfully performed into LNCs for animal experiments. A reduction of tumor volume and mass was proved after siBcl-2 LNC treatment and Ansa-FcDiOH LNC treatment, individually (around 25%). Finally, the association of both components into the same LNCs increased the reduction of tumor volume to about 50% compared to the control group. In conclusion, LNCs appeared to provide a promising tool for the co-encapsulation of a metal-based drug and siRNA.
Collapse
Affiliation(s)
- Pauline Resnier
- MINT, UNIV Angers, INSERM, CNRS, Université Bretagne Loire, IBS-CHU, 4 rue Larrey, F-49933 Angers, France.
| | - Natacha Galopin
- SCAHU - Faculté de Médecine, Pavillon Ollivier, rue Haute de Reculée, F-49933 Angers, France.
| | - Yann Sibiril
- INSERM U1078 - Equipe 'Transfert de gènes et thérapie génique', Faculté de Médecine, 22 avenue Camille Desmoulins, CS 93837, F-29238 Brest, Cedex 3, France; CHRU de Brest, Service de Génétique Moléculaire et d'histocompatibilité, 5 avenue Maréchal Foch, 29609 Brest, France.
| | - Anne Clavreul
- MINT, UNIV Angers, INSERM, CNRS, Université Bretagne Loire, IBS-CHU, 4 rue Larrey, F-49933 Angers, France.
| | - Jérôme Cayon
- MINT, UNIV Angers, INSERM, CNRS, Université Bretagne Loire, IBS-CHU, 4 rue Larrey, F-49933 Angers, France; PACeM (Plateforme d'Analyse Cellulaire et Moléculaire), SFR ICAT 4208, Université d'Angers, 4 rue Larrey, F-49933 Angers, France.
| | - Alessandro Briganti
- MINT, UNIV Angers, INSERM, CNRS, Université Bretagne Loire, IBS-CHU, 4 rue Larrey, F-49933 Angers, France.
| | - Pierre Legras
- SCAHU - Faculté de Médecine, Pavillon Ollivier, rue Haute de Reculée, F-49933 Angers, France.
| | - Anne Vessières
- CNRS, UMR 8232, ENSCP, 11 rue P. et M. Curie, F-75231 Paris Cedex05, France.
| | - Tristan Montier
- INSERM U1078 - Equipe 'Transfert de gènes et thérapie génique', Faculté de Médecine, 22 avenue Camille Desmoulins, CS 93837, F-29238 Brest, Cedex 3, France; CHRU de Brest, Service de Génétique Moléculaire et d'histocompatibilité, 5 avenue Maréchal Foch, 29609 Brest, France.
| | - Gérard Jaouen
- CNRS, UMR 8232, ENSCP, 11 rue P. et M. Curie, F-75231 Paris Cedex05, France.
| | - Jean-Pierre Benoit
- MINT, UNIV Angers, INSERM, CNRS, Université Bretagne Loire, IBS-CHU, 4 rue Larrey, F-49933 Angers, France.
| | - Catherine Passirani
- MINT, UNIV Angers, INSERM, CNRS, Université Bretagne Loire, IBS-CHU, 4 rue Larrey, F-49933 Angers, France.
| |
Collapse
|
26
|
Cikankowitz A, Clavreul A, Tétaud C, Lemaire L, Rousseau A, Lepareur N, Dabli D, Bouchet F, Garcion E, Menei P, Couturier O, Hindré F. Characterization of the distribution, retention, and efficacy of internal radiation of 188Re-lipid nanocapsules in an immunocompromised human glioblastoma model. J Neurooncol 2016; 131:49-58. [PMID: 27783195 DOI: 10.1007/s11060-016-2289-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2016] [Accepted: 10/09/2016] [Indexed: 10/20/2022]
Abstract
Internal radiation strategies hold great promise for glioblastoma (GB) therapy. We previously developed a nanovectorized radiotherapy that consists of lipid nanocapsules loaded with a lipophilic complex of Rhenium-188 (LNC188Re-SSS). This approach resulted in an 83 % cure rate in the 9L rat glioma model, showing great promise. The efficacy of LNC188Re-SSS treatment was optimized through the induction of a T-cell immune response in this model, as it is highly immunogenic. However, this is not representative of the human situation where T-cell suppression is usually encountered in GB patients. Thus, in this study, we investigated the efficacy of LNC188Re-SSS in a human GB model implanted in T-cell deficient nude mice. We also analyzed the distribution and tissue retention of LNC188Re-SSS. We observed that intratumoral infusion of LNCs by CED led to their complete distribution throughout the tumor and peritumoral space without leakage into the contralateral hemisphere except when large volumes were used. Seventy percent of the 188Re-SSS activity was present in the tumor region 24 h after LNC188Re-SSS injection and no toxicity was observed in the healthy brain. Double fractionated internal radiotherapy with LNC188Re-SSS triggered survival responses in the immunocompromised human GB model with a cure rate of 50 %, which was not observed with external radiotherapy. In conclusion, LNC188Re-SSS can induce long-term survival in an immunosuppressive environment, highlighting its potential for GB therapy.
Collapse
Affiliation(s)
- Annabelle Cikankowitz
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France.,AMaROC, ONIRIS, Ecole Nationale Véterinaire de Nantes, Nantes, France.,PRIMEX (Plateforme de Radiobiologie et d'Imagerie Expérimentale), Université d'Angers, Angers, France
| | - Anne Clavreul
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France. .,Service de Neurochirurgie, CHU d'Angers, Angers, France.
| | - Clément Tétaud
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France.,PRIMEX (Plateforme de Radiobiologie et d'Imagerie Expérimentale), Université d'Angers, Angers, France
| | - Laurent Lemaire
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France
| | - Audrey Rousseau
- Laboratoire de Pathologie Cellulaire et Tissulaire, CHU d'Angers, Angers, France
| | - Nicolas Lepareur
- Centre Régional de Lutte Contre le Cancer (CRLCC) Eugène Marquis, Rennes, France
| | - Djamel Dabli
- Médecine Nucléaire et Biophysique, CHU d'Angers, Angers, France
| | - Francis Bouchet
- Médecine Nucléaire et Biophysique, CHU d'Angers, Angers, France
| | - Emmanuel Garcion
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France
| | - Philippe Menei
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France.,Service de Neurochirurgie, CHU d'Angers, Angers, France
| | - Olivier Couturier
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France.,Médecine Nucléaire et Biophysique, CHU d'Angers, Angers, France
| | - François Hindré
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France.,PRIMEX (Plateforme de Radiobiologie et d'Imagerie Expérimentale), Université d'Angers, Angers, France
| |
Collapse
|
27
|
Scalcon V, Citta A, Folda A, Bindoli A, Salmain M, Ciofini I, Blanchard S, de Jésús Cázares-Marinero J, Wang Y, Pigeon P, Jaouen G, Vessières A, Rigobello MP. Enzymatic oxidation of ansa-ferrocifen leads to strong and selective thioredoxin reductase inhibition in vitro. J Inorg Biochem 2016; 165:146-151. [PMID: 27567149 DOI: 10.1016/j.jinorgbio.2016.08.005] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Revised: 07/13/2016] [Accepted: 08/04/2016] [Indexed: 12/01/2022]
Abstract
This paper reports the inhibitory effect on the cytosolic thioredoxin reductase (TrxR1) in vitro by the ansa-ferrocifen derivative (ansa-FcdiOH, 1). We found that 1 decreased only slightly enzyme activity (IC50=8μM), while 1*, the species generated by enzymatic oxidation by the HRP (horseradish peroxidase)/H2O2 mixture, strongly inhibited TrxR1 (IC50=0.15μM). At the same concentrations, neither 1 nor 1* had effect on glutathione reductase (GR). The most potent TrxR1 inhibitor did not appear to be the corresponding quinone methide as it was the case for ferrocifens of the acyclic series, or the stabilized carbocation as in the osmocifen series, but rather the quinone methide radical. This hypothesis was confirmed by ab-initio calculations of the species generated by oxidation of 1 and by EPR spectroscopy. BIAM (biotin-conjugated iodoacetamide) assay showed that 1* targeted both cysteine and selenocysteine of the C-terminal redox center of TrxR1.
Collapse
Affiliation(s)
- Valeria Scalcon
- Dipartimento di Scienze Biomediche, Università di Padova, Via Ugo Bassi 58/b, 35131 Padova, Italy
| | - Anna Citta
- Dipartimento di Scienze Biomediche, Università di Padova, Via Ugo Bassi 58/b, 35131 Padova, Italy
| | - Alessandra Folda
- Dipartimento di Scienze Biomediche, Università di Padova, Via Ugo Bassi 58/b, 35131 Padova, Italy
| | - Alberto Bindoli
- Istituto di Neuroscienze (CNR) Sezione di Padova, c/o Dipartimento di Scienze Biomediche, Via Ugo Bassi, 58/b, 35131 Padova, Italy
| | - Michèle Salmain
- Sorbonne Universités, UPMC Univ Paris 06, CNRS, Institut Parisien de Chimie Moléculaire (IPCM), 75005 Paris, France
| | - Ilaria Ciofini
- PSL Research University, Chimie ParisTech, 11 rue Pierre et Marie Curie, 75005 Paris, France
| | - Sébastien Blanchard
- Sorbonne Universités, UPMC Univ Paris 06, CNRS, Institut Parisien de Chimie Moléculaire (IPCM), 75005 Paris, France
| | | | - Yong Wang
- Sorbonne Universités, UPMC Univ Paris 06, CNRS, Institut Parisien de Chimie Moléculaire (IPCM), 75005 Paris, France; PSL Research University, Chimie ParisTech, 11 rue Pierre et Marie Curie, 75005 Paris, France
| | - Pascal Pigeon
- Sorbonne Universités, UPMC Univ Paris 06, CNRS, Institut Parisien de Chimie Moléculaire (IPCM), 75005 Paris, France; PSL Research University, Chimie ParisTech, 11 rue Pierre et Marie Curie, 75005 Paris, France
| | - Gérard Jaouen
- Sorbonne Universités, UPMC Univ Paris 06, CNRS, Institut Parisien de Chimie Moléculaire (IPCM), 75005 Paris, France; PSL Research University, Chimie ParisTech, 11 rue Pierre et Marie Curie, 75005 Paris, France
| | - Anne Vessières
- Sorbonne Universités, UPMC Univ Paris 06, CNRS, Institut Parisien de Chimie Moléculaire (IPCM), 75005 Paris, France
| | - Maria Pia Rigobello
- Dipartimento di Scienze Biomediche, Università di Padova, Via Ugo Bassi 58/b, 35131 Padova, Italy.
| |
Collapse
|
28
|
Scalcon V, Top S, Lee HZS, Citta A, Folda A, Bindoli A, Leong WK, Salmain M, Vessières A, Jaouen G, Rigobello MP. Osmocenyl-tamoxifen derivatives target the thioredoxin system leading to a redox imbalance in Jurkat cells. J Inorg Biochem 2016; 160:296-304. [DOI: 10.1016/j.jinorgbio.2016.04.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2016] [Revised: 03/17/2016] [Accepted: 04/03/2016] [Indexed: 01/27/2023]
|
29
|
Nanostructured materials functionalized with metal complexes: In search of alternatives for administering anticancer metallodrugs. Coord Chem Rev 2016. [DOI: 10.1016/j.ccr.2016.01.001] [Citation(s) in RCA: 149] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
30
|
Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art. J Control Release 2016; 227:23-37. [PMID: 26892752 DOI: 10.1016/j.jconrel.2016.02.026] [Citation(s) in RCA: 158] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2016] [Revised: 02/12/2016] [Accepted: 02/13/2016] [Indexed: 01/26/2023]
Abstract
Glioblastoma multiforme, a grade IV glioma, is the most frequently occurring and invasive primary tumor of the central nervous system, which causes about 4% of cancer-associated-deaths, making it one of the most fatal cancers. With present treatments, using state-of-the-art technologies, the median survival is about 14 months and 2 year survival rate is merely 3-5%. Hence, novel therapeutic approaches are urgently necessary. However, most drug molecules are not able to cross the blood-brain barrier, which is one of the major difficulties in glioblastoma treatment. This review describes the features of blood-brain barrier, and its anatomical changes with different stages of tumor growth. Moreover, various strategies to improve brain drug delivery i.e. tight junction opening, chemical modification of the drug, efflux transporter inhibition, convection-enhanced delivery, craniotomy-based drug delivery and drug delivery nanosystems are discussed. Nanocarriers are one of the highly potential drug transport systems that have gained huge research focus over the last few decades for site specific drug delivery, including drug delivery to the brain. Properly designed nanocolloids are capable to cross the blood-brain barrier and specifically deliver the drug in the brain tumor tissue. They can carry both hydrophilic and hydrophobic drugs, protect them from degradation, release the drug for sustained period, significantly improve the plasma circulation half-life and reduce toxic effects. Among various nanocarriers, liposomes, polymeric nanoparticles and lipid nanocapsules are the most widely studied, and are discussed in this review. For each type of nanocarrier, a general discussion describing their composition, characteristics, types and various uses is followed by their specific application to glioblastoma treatment. Moreover, some of the main challenges regarding toxicity and standardized evaluation techniques are narrated in brief.
Collapse
|
31
|
Safwat S, Hathout RM, Ishak RA, Mortada ND. Augmented simvastatin cytotoxicity using optimized lipid nanocapsules: a potential for breast cancer treatment. J Liposome Res 2016; 27:1-10. [DOI: 10.3109/08982104.2015.1137313] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Sally Safwat
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
| | - Rania M. Hathout
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
| | - Rania A. Ishak
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
| | - Nahed D. Mortada
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
| |
Collapse
|
32
|
Wani WA, Baig U, Shreaz S, Shiekh RA, Iqbal PF, Jameel E, Ahmad A, Mohd-Setapar SH, Mushtaque M, Ting Hun L. Recent advances in iron complexes as potential anticancer agents. NEW J CHEM 2016. [DOI: 10.1039/c5nj01449b] [Citation(s) in RCA: 99] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The iron complexes discussed in this review highlight their promising future as anticancer agents.
Collapse
Affiliation(s)
- Waseem A. Wani
- Institute of Bioproduct Development
- Universiti Teknologi Malaysia
- 81310 UTM Skudai
- Malaysia
| | - Umair Baig
- Center of Excellence for Scientific Research Collaboration with MIT
- King Fahd University of Petroleum and Minerals
- Dhahran 31261
- Saudi Arabia
| | - Sheikh Shreaz
- Oral Microbiology Laboratory
- Department of Bioclinical Sciences
- Faculty of Dentistry
- Health Sciences Center
- Kuwait University
| | - Rayees Ahmad Shiekh
- Department of Chemistry
- Faculty of Science
- Taibah University
- Al Madinah Al Munawarrah
- Saudi Arabia
| | | | - Ehtesham Jameel
- Department of Chemistry
- B. R. Ambedkar Bihar University
- Muzaffarpur
- India
| | - Akil Ahmad
- Center of Lipids Engineering and Applied Research
- Ibnu Sina Institute for Industrial and Scientific Research
- Universiti Teknologi Malaysia
- 81310 UTM Skudai
- Malaysia
| | - Siti Hamidah Mohd-Setapar
- Center of Lipids Engineering and Applied Research
- Ibnu Sina Institute for Industrial and Scientific Research
- Universiti Teknologi Malaysia
- 81310 UTM Skudai
- Malaysia
| | - Md. Mushtaque
- Department of Physical and Molecular Sciences (Chemistry)
- Al-Falah University
- Faridabad
- India
| | - Lee Ting Hun
- Institute of Bioproduct Development
- Universiti Teknologi Malaysia
- 81310 UTM Skudai
- Malaysia
| |
Collapse
|
33
|
Beauperin M, Top S, Richard MA, Plażuk D, Pigeon P, Toma S, Poláčková V, Jaouen G. The length of the bridging chain in ansa-metallocenes influences their antiproliferative activity against triple negative breast cancer cells (TNBC). Dalton Trans 2016; 45:13126-34. [DOI: 10.1039/c6dt01640e] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
[n]Ferrocenophane and [n]ruthenocenophane derivatives have been synthesized and their antiproliferative activity evaluated against MDA-MB-231 cells.
Collapse
Affiliation(s)
| | - Siden Top
- Sorbonne Universités
- UPMC Univ Paris 6
- UMR 8232
- IPCM
- F-75005 Paris
| | | | - Damian Plażuk
- University of Lodz
- Faculty of Chemistry
- Department of Organic Chemistry
- Lodz 91-403
- Poland
| | - Pascal Pigeon
- Sorbonne Universités
- UPMC Univ Paris 6
- UMR 8232
- IPCM
- F-75005 Paris
| | - Stefan Toma
- Faculty of Natural Sciences
- Comenius University
- SK-84215 Bratislava
- Slovakia
| | - Viera Poláčková
- Faculty of Natural Sciences
- Comenius University
- SK-84215 Bratislava
- Slovakia
| | - Gérard Jaouen
- Sorbonne Universités
- UPMC Univ Paris 6
- UMR 8232
- IPCM
- F-75005 Paris
| |
Collapse
|
34
|
Wang Y, Pigeon P, Top S, McGlinchey MJ, Jaouen G. Organometallic Antitumor Compounds: Ferrocifens as Precursors to Quinone Methides. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201503048] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
35
|
Wang Y, Pigeon P, Top S, McGlinchey MJ, Jaouen G. Organometallic Antitumor Compounds: Ferrocifens as Precursors to Quinone Methides. Angew Chem Int Ed Engl 2015; 54:10230-3. [DOI: 10.1002/anie.201503048] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Indexed: 02/05/2023]
|
36
|
Abstract
The mechanisms of action of ferrocifens depend on several features: chemical structures, used concentrations, nature of cancer cells.
Collapse
Affiliation(s)
- Gérard Jaouen
- Sorbonne Universités
- UPMC Univ Paris 06
- IPCM
- F-75005 Paris
- France
| | - Anne Vessières
- Sorbonne Universités
- UPMC Univ Paris 06
- IPCM
- F-75005 Paris
- France
| | - Siden Top
- Sorbonne Universités
- UPMC Univ Paris 06
- IPCM
- F-75005 Paris
- France
| |
Collapse
|